Fludarabine (Fludara) — Clinical FAQs

Question 1

What is Fludarabine FDA-approved to treat?

Accepted Answer

Fludarabine is FDA-approved for the following oncology indications: 1. B-cell chronic lymphocytic leukemia (CLL), second-line after at least one prior alkylating agent regimen (FDA approved 1991, pivotal MDACC single-arm trials).

Question 2

How does Fludarabine work (mechanism of action)?

Accepted Answer

Fludarabine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form (F-ara-ATP). F-ara-ATP competitively inhibits DNA polymerase alpha and epsilon, ribonucleotide reductase, and DNA primase, thereby blocking DNA synthesis and repair. Incorporation of F-ara-ATP into DNA leads to chain termination and induction of apoptosis. It also inhibits RNA synthesis by incorporating into RNA strands.

Question 3

How is Fludarabine administered?

Accepted Answer

Fludarabine is administered Intravenous (IV) or Oral (PO). IV: 25 mg/m²/day over 30 minutes for 5 consecutive days every 28 days.

Question 4

What are the most common side effects of Fludarabine?

Accepted Answer

The most commonly reported side effects of Fludarabine (≥10% incidence) include: Myelosuppression (neutropenia, thrombocytopenia, anemia), Fatigue and weakness, Nausea and vomiting, Fever and chills, Infection (bacterial, viral, opportunistic) and others (10 total). Consult your oncologist for complete prescribing information.

Question 5

Does Fludarabine have a black box warning?

Accepted Answer

Yes. Fludarabine carries FDA black box warning(s) regarding: 1. Severe neurologic toxicity including blindness, coma, and death reported at high doses; delayed neurotoxicity can occur at standard doses 2. Autoimmune hemolytic anemia (sometimes fatal) has been reported; discontinue fludarabine if hemolysis occurs 3. Severe bone marrow suppression (neutropenia, thrombocytopenia, anemia) is dose-limiting

Question 6

Is Fludarabine safe during pregnancy?

Accepted Answer

Fludarabine pregnancy safety: Category D — fludarabine is teratogenic and embryotoxic in animal studies. Avoid use during pregnancy. Women of childbearing potential should use effective contraception during and for 6 months after therapy.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Fludarabine — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms